|

JANX013 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Janux Therapeutics1

Indications

  • Castration-Resistant Prostate Cancer (CRPC)1
  • Metastatic Castration-Resistant Prostate Cancer Patients1
  • Metastatic Prostate Cancer1
  • Prostate Cancer1
  • Cancer1

Nashville, Tennessee1 trial

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

Sarah Cannon Research Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.